Stockwatch: Pandora’s Interim Analysis
The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?
You may also be interested in...
Drug failures in Phase III and value-based pricing were two forces affecting Horizon and Vertex, respectively, last week. Biogen and Teva have shown that value, at least, is a force to be argued with.
A drug approval at Sarepta, two acquisitions by Allergan and $15bn worth of dry powder at Takeda has prompted “biotech off to the races” commentaries by analysts and the press. This froth will probably dissipate.
Shares in Geron dropped by nearly 20% to $2.30 on NASDAQ on Sept. 12 following interim clinical data for its lead product, the anticancer imetelstat, from trials conducted by its partner Janssen.